EuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
EuroHospital Varna is the largest private hospital in the city of Varna, Bulgaria, specializing in the treatment of orthopedic, surgical, gastroenterological and urological conditions. Over the years, the hospital has built a strong reputation in Varna and throughout Northeast Bulgaria as a leading center for orthopedics and traumatology. With a team of more than 100 specialists, including leading and well-established doctors in Bulgaria, the hospital attracts patients from all over the country, as well as international patients through cooperation with leading assistance companies in Europe.
Intermedica Group is one of the leading distributors of high-technology medical devices and equipment in Bulgaria and the region, supporting hospitals, clinics and physicians in improving patient care, efficiency and cost optimization. Over the past 15 years, the group has become a preferred partner to leading medical manufacturers and more than 270 healthcare institutions.
Oaklins’ team in Bulgaria acted as the exclusive M&A advisor to the founders of EuroHospital Varna, supporting them throughout the negotiation, due diligence and sale process.
Talk to the deal team
Related deals
Rare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more